Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
DuPont Co. and the Dow Chemical Co. have cleared a major hurdle to their tie-up with conditional approval from the Competition Commission of India for their $78.5 billion merger. There are only two major countries left to approve the deal — Canada and the U.S.
DuPont confirmed on June 12 that it has received conditional clearance from the Indian antitrust watchdog. India is one of a few big jurisdictions that had yet to clear the deal, and it is an important market for both companies. The companies said in a statement that they remain on track to close the merger in August, the contractual deadline for the deal.
The companies said in an email to Bloomberg BNA that they agreed to “remedies” in Indian markets related to grape fungicides targeting the sac funghi Ascomycota and those handling of “low graft” maleic-anhydride (MAH) grafted polymers, a type of plastic.
The companies “continue to engage constructively with regulators in the remaining jurisdictions,” Dow media relations leader Jarrod Erpelding said in an email.
The U.S. and Canada stand out as two jurisdictions that have not yet cleared the deal, but it has garnered many of the clearances necessary to proceed with the first stage of the planned merger and spin-off into three separate industry-based companies.
Because the process in the U.S. and Canada is confidential, information on where the companies stand in those merger reviews is unavailable. Canada’s antitrust agency publicly announces its merger decisions on a monthly basis only, but a spokeswoman confirmed June 9 that the bureau is still reviewing the merger.
The deal has already cleared several other barriers. China and Brazil approved the merger conditioned on divestitures in May, and the European Commission cleared it with substantial divestiture requirements in March, including the sale of major parts of Dupont’s global pesticide business.
Shareholder votes on the deal, announced in December 2015, passed in June 2016.
To contact the reporter on this story: Eleanor Tyler in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Fawn Johnson at email@example.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)